Skip to Content
Merck
  • IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.

IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.

Neuro-oncology (2013-07-24)
Chunzhi Zhang, Lynette M Moore, Xia Li, W K Alfred Yung, Wei Zhang
ABSTRACT

Isocitrate dehydrogenase (IDH) enzymes have recently become a focal point for research aimed at understanding the biology of glioma. IDH1 and IDH2 are mutated in 50%-80% of astrocytomas, oligodendrogliomas, oligoastrocytomas, and secondary glioblastomas but are seldom mutated in primary glioblastomas. Gliomas with IDH1/2 mutations always harbor other molecular aberrations, such as TP53 mutation or 1p/19q loss. IDH1 and IDH2 mutations may serve as prognostic factors because patients with an IDH-mutated glioma survive significantly longer than those with an IDH-wild-type tumor. However, the molecular pathogenic role of IDH1/2 mutations in the development of gliomas is unclear. The production of 2-hydroxyglutarate and enhanced NADP+ levels in tumor cells with mutant IDH1/2 suggest mechanisms through which these mutations contribute to tumorigenesis. Elucidating the pathogenesis of IDH mutations will improve understanding of the molecular mechanisms of gliomagenesis and may lead to development of a new molecular classification system and novel therapies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Isocitric Dehydrogenase (NADP) from porcine heart, Type I, 0.5-3.0 unit/mg solid (plus numerous enzyme activities associated with porcine heart)
Sigma-Aldrich
Isocitric Dehydrogenase (NADP) from porcine heart, Type IV, buffered aqueous glycerol solution, 3-20 units/mg protein
Sigma-Aldrich
Isocitrate Dehydrogenase 1 (NADP+) human, recombinant, expressed in Sf9 cells, ≥90% (SDS-PAGE)